IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.
Reijers ILM, Rao D, Versluis JM, Menzies AM, Dimitriadis P, Wouters MW, Spillane AJ, Klop WMC, Broeks A, Bosch LJW, Lopez-Yurda M, van Houdt WJ, Rawson RV, Grijpink-Ongering LG, Gonzalez M, Cornelissen S, Bouwman J, Sanders J, Plasmeijer E, Elshot YS, Scolyer RA, van de Wiel BA, Peeper DS, van Akkooi ACJ, Long GV, Blank CU.
Reijers ILM, et al. Among authors: elshot ys.
J Exp Med. 2023 May 1;220(5):e20221952. doi: 10.1084/jem.20221952. Epub 2023 Mar 15.
J Exp Med. 2023.
PMID: 36920329
Free PMC article.
Clinical Trial.